The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk factor analyses of severe cicatricial stricture after chemoradiotherapy for stage II/III (T3) esophageal carcinoma.
 
Natsuko Tsushita
No Relationships to Disclose
 
Yoshitaka Honma
Speakers' Bureau - Nihonkayaku; Novartis; Taiho Pharmaceutical
 
Kengo Nagashima
No Relationships to Disclose
 
Takahiro Miyamoto
No Relationships to Disclose
 
Shoko Nakamura
No Relationships to Disclose
 
Rei Umezawa
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Hirokazu Shoji
No Relationships to Disclose
 
Atsuo Takashima
Speakers' Bureau - Chugai Pharma; Takeda
 
Satoru Iwasa
Research Funding - Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; Novartis
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Lilly; Nippon Kayaku; Pfizer; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Nippon Kayaku; Novartis; Otsuka; Taiho Pharmaceutical
Research Funding - Merck Serono; MSD; Novartis; Ono Pharmaceutical; Shionogi
 
Tetsuya Hamaguchi
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - NanoCarrier
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Jun Itami
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)